1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2032

Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2032

  • May 2022
  • 80 pages
  • ID: 6276116
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘focal segmental glomerulosclerosis (FSGS) – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of focal segmental glomerulosclerosis (FSGS) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Focal segmental glomerulosclerosis (FSGS): Disease Understanding

Focal segmental glomerulosclerosis (FSGS) Overview
Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed. It typically presents with nephrotic syndrome with characterized proteinuria and obliteration or failure of glomerular capillary loops by increased extracellular matrix in glomeruli capillary tufts. However, the capillary injury does not occupy the entire glomerulus.
The clinical features of FSGS are the features of nephrotic syndrome and include peripheral edema, marked proteinuria (with or without a nephrotic range), hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. It may be found either in primary or secondary forms.
Primary FSGS sometimes has no identifiable cause or known etiology (idiopathic) and is linked to genetic mutations in podocyte-specific proteins (e.g., membrane and podocyte slit diaphragm proteins), while secondary FSGS may occur in response to previous glomerular injury, glomerular hypertension, hypertrophy, drug toxicity (e.g., pamidronate, Adriamycin), some malignancies or viral infections (e.g., HIV infection), obesity, and reduced renal mass. FSGS is one of the most common causes of primary glomerular disease in children and adults, which may progress to end-stage renal disease (ESRD) with a relatively high risk.
FSGS is further classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion. Primary or idiopathic FSGS is considered to be related to podocyte injury, and the pathogenesis of podocyte injury has been actively investigated. Several circulating factors affecting the podocyte permeability barrier have been proposed but not proven to cause FSGS. Genetic alterations may also cause FSGS. These genes mainly regulate the slit diaphragm structure, actin cytoskeleton of podocytes, and foot process structure. The mode of inheritance and age of onset is different according to the gene involved.

Focal segmental glomerulosclerosis (FSGS): Epidemiology
The focal segmental glomerulosclerosis (FSGS) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical and forecasted focal segmental glomerulosclerosis (FSGS) epidemiology segmented as the Diagnosed Prevalence of focal Segmental Glomerulosclerosis, Gender-specific cases of Focal Segmental Glomerulosclerosis, and Type-specific cases of Focal Segmental Glomerulosclerosis. The report includes the prevalent scenario of Focal segmental glomerulosclerosis (FSGS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019–2032.

Country-wise Focal segmental glomerulosclerosis (FSGS) Epidemiology
The epidemiology segment also provides the focal segmental glomerulosclerosis (FSGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed population of focal segmental glomerulosclerosis (FSGS) in the 7MM countries was close to 220,000 cases in 2021.
As per the estimates, the United States had the highest diagnosed prevalence focal segmental glomerulosclerosis (FSGS) population in 2021. Among the EU5 countries, Germany had the highest diagnosed prevalent population of Focal segmental glomerulosclerosis (FSGS) with more than 23,000 cases, followed by France in 2021. On the other hand, Spain had the lowest diagnosed prevalent population of ~13,000 cases in 2021.

Scope of the Report
• Focal segmental glomerulosclerosis report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• Focal segmental glomerulosclerosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Focal segmental glomerulosclerosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Focal segmental glomerulosclerosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of focal segmental glomerulosclerosis.
• The report provides the segmentation of the focal segmental glomerulosclerosis epidemiology by diagnosed prevalent cases of focal segmental glomerulosclerosis in the 7MM.
• The report provides the segmentation of the focal segmental glomerulosclerosis epidemiology by gender-specific cases of focal segmental glomerulosclerosis in the 7MM.
• The report provides the segmentation of the focal segmental glomerulosclerosis epidemiology by types-specific cases of focal segmental glomerulosclerosis in the 7MM.

Report Highlights

• 11-year Forecast of focal segmental glomerulosclerosis epidemiology
• 7MM Coverage
• Prevalent cases of focal segmental glomerulosclerosis
• Type-specific cases of focal segmental glomerulosclerosis
• Gender-specific cases of focal segmental glomerulosclerosis

KOL Views
We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered
• What are the major factors that will drive the change in the patient population in focal segmental glomerulosclerosis during the forecast period (2019–2032)?
• What are the key findings pertaining to the focal segmental glomerulosclerosis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
• What would be the total number of patients with focal segmental glomerulosclerosis across the 7MM during the forecast period (2019–2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?
• What are the disease risk, burdens, and unmet needs of focal segmental glomerulosclerosis?
• What are the currently available treatments for focal segmental glomerulosclerosis?

Reasons to buy
Focal segmental glomerulosclerosis (FSGS) Epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global focal segmental glomerulosclerosis (FSGS) market
• Quantify patient populations in the global focal segmental glomerulosclerosis market to improve product design, pricing, and launch plans
• Understand the magnitude of the focal segmental glomerulosclerosis population by its diagnosed prevalent cases.
• Understand the magnitude of the Focal segmental glomerulosclerosis population by its gender-specific cases.
• Understand the magnitude of the focal segmental glomerulosclerosis (FSGS) population by its type-specific cases of focal segmental glomerulosclerosis.
• The focal segmental glomerulosclerosis (FSGS) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The focal segmental glomerulosclerosis (FSGS) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Chronic Kidney Disease Epidemiology Analysis and Forecast, 2021-2031

  • $ 3995
  • May 2022
  • 36 pages

Chronic Kidney Disease Epidemiology Analysis and Forecast, 2021-2031 Summary Chronic kidney disease (CKD) (ICD-10 = N18) is a condition characterized by a gradual loss of kidney function over time.This ...

  • United States
  • World
  • Chronic Disease
  • Epidemiology
  • Industry analysis
  • Prescription Drug Sales
  • Anemia Prevalence

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on